Cell No. : Cell Name
RCB1033 : NOS-2
update : 2024/10/02
|
| Comment | Human osteosarcoma producing osteoid in vitro and in vivo(mouse). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Motoyama, Teiichi
|
| Originator |
Hotta, Tetsuo & Motoyama, Teiichi
|
| Year of deposit |
1994
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
11 years
|
| Tissue |
bone
|
| Disease name |
osteosarcoma
|
| Metastatic ability |
No
|
| Classification |
cancer
|
| Year of origin |
1989
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_3351
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 4-8 split
|
| SC frequency |
|
Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
46-116(50) : /56(3),57(5),58(4),59(4),60(5),61(3)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
5
|
| User's Publication |
|
21832
Kojima Y, Fujieda S, Zhou L, Takikawa M, Kuramochi K, Furuya T, Mizumoto A, Kagaya N, Kawahara T, Shin-Ya K, Dan S, Tomida A, Ishikawa F, Sadaie M.
Cytochrome P450 2J2 is required for the natural compound austocystin D to elicit cancer cell toxicity.
Cancer Sci
2024
PubMed ID: 39009033
DOI: 10.1111/cas.16289
|
|
22145
Chow T, Humble W, Lucarelli E, Onofrillo C, Choong PF, Di Bella C, Duchi S.
Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.
iScience
2024
27(9):110251
PubMed ID: 39286504
DOI: 10.1016/j.isci.2024.110251
|
|
17357
Hayashi T, Yamamoto N, Kurosawa G, Tajima K, Kondo M, Hiramatsu N, Kato Y, Tanaka M, Yamaguchi H, Kurosawa Y, Yamada H, Fujita N.
A Novel High-Throughput Screening Method for a Human Multicentric Osteosarcoma-Specific Antibody and Biomarker Using a Phage Display-Derived Monoclonal Antibody
Cancers (Basel)
2022
14(23):5829
PubMed ID: 36497311
DOI: 10.3390/cancers14235829
|
|
6431
Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M, Furukawa K.
Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.
Cancer Sci
2012
103(9):1656-64
PubMed ID: 22632091
DOI: 10.1111/j.1349-7006.2012.02344.x
|
|
2671
Nagano, Satoshi, Yuge, Kentaro, Fukunaga, Mari, Terazaki, Yasuhiro, Fujiwara, Hisayoshi, Komiya, Setsuro, Kosai, Ken-Ichiro
Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: novel concepts for successful cytokine gene therapy.
Int J Oncol
2004
24:549-58
PubMed ID: 14767539
|
Back
Top
CELL BANK Website